96例外周T细胞非霍奇金淋巴瘤预后分析

目的：分析外周T细胞淋巴瘤的临床特征、近期疗效、远期生存及预后因素。方法：对96例患者的临床特征、治疗效果及预后因素进行分析。外周T细胞淋巴瘤-非特异型（PTCL-U）66例,间变大细胞性淋巴瘤（ALCL）6例,NK/T淋巴廇（NK/TCL）17例,肠道T细胞性淋巴瘤（ITCL）5例,血管免疫母T细胞性淋巴瘤（AITCL）2例。结果：96例患者中89例接受CHOP方案为主的联合化疗,有效率（RR）为88.8%,完全缓解（CR）率为57.3%。中位随访时间30（2～98）个月,死亡52例,中位生存期31.9个月,1、3、5年生存率分别为83.3%、42.7%、35.1%。多因素分析结果显示,IPI评分是PTCL的独立预后指标（P〈0.05）。结论：外周T细胞淋巴瘤常规化疗近期疗效尚可,但远期生存率低,预后不良,需进一步探索新的治疗策略。

Clinical Analysis of Prognosis for 96 Patients with Peripheral T-cell Lymphoma

Objective: To summarize and analyze the clinical characteristics, treatment outcome, overall survival rates and prognosis of peripheral T-cell lymphoma (PTCL) patients. Methods: Data from 96 patients with PTCL were analyzed retrospectively. Results: Histopathological subgroups included 66 PTCL-unspecified (PTCL-U) cases, 6 anaplastic large cell lymphoma (ALCL) cases, 17 angiocentric lymphoma(NK/T-cell lymphoma, NK/TCL) cases, 5 intestinal T-cell lymphoma cases and 2 angioimmunoblastic T-cell lymphoma cases. Most of the patients were treated with combined chemotherapy(CHOP regimen). Overall response rate was 88.8% with 57.3% complete remission (CR) rates for 89 evaluable patients. The median survival time (MST) was 31.9 months. The 1-, 3-, and 5-year overall survival(OS) rates were 83.3%, 42.7% and 35.1%, respectively. Multivariate analysis showed that IPI score was an independent prognostic factor for PTCL(P<0.05). Conclusion: Although conventional chemotherapy yields high response rates for PTCL, the long-term survival is still poor. Further investigation for optional treatment is needed.